Source comparison
BPC-157 Gut Health: Research vs Claims Comparison
Accelerates gastric ulcer healing Strong. Multiple rodent studies show 60–72% faster healing vs controls (European Journal of Pharmacology, J Physiology Paris) VEGF upregulation, NO pathway modulation, direct mucosal repair Mechanistically sound; lacks Phase 3
This comparison does not assign a generated winner or score.
- Accelerates gastric ulcer healing
- Strong. Multiple rodent studies show 60–72% faster healing vs controls (European Journal of Pharmacology, J Physiology Paris)
- VEGF upregulation, NO pathway modulation, direct mucosal repair
- Mechanistically sound; lacks Phase 3 human data but consistency across models is notable
- Reduces inflammatory bowel disease severity
- Moderate. Colitis models show reduced TNF-alpha, preserved gut architecture
- Anti-inflammatory cytokine modulation, barrier integrity preservation
- Promising in preclinical models; clinical translation uncertain without human trials
- Repairs leaky gut syndrome
- Indirect. Tight junction stabilization observed in barrier integrity assays (TEER measurements)
- Tight junction protein stabilization under inflammatory stress
- Mechanism is relevant, but 'leaky gut' isn't a clinical diagnosis; evidence is inferential
- Supports systemic healing beyond gut
- Moderate. Tendon, muscle, and ligament studies show similar angiogenic effects
- VEGF/EGF upregulation, collagen synthesis across tissue types
- Suggests the peptide isn't gut-specific; angiogenesis mechanism applies broadly
- Oral administration is effective
- Moderate. Gastric ulcer studies used oral dosing with positive outcomes
- Survives gastric acid, exerts local mucosal effects before systemic absorption
- Unusual for peptides; suggests stability in low-pH environments or rapid mucosal binding